Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 98%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
21,600
Total Claims
$2.3M
Drug Cost
709
Beneficiaries
$3,181
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+97%
Opioid rate vs peers
5.1% vs 2.6% avg
+198%
Cost per patient vs peers
$3,181 vs $1,068 avg
+65%
Brand preference vs peers
14.9% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
5.1%
Opioid Rate
1,097
Opioid Claims
$32K
Opioid Cost
5.8%
Long-Acting Rate
Brand vs Generic
Brand: 3,197 claims · $1.7M
Generic: 18,276 claims · $516K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 261 | $314K |
| Apixaban | 287 | $161K |
| Tirzepatide | 78 | $127K |
| Sitagliptin Phosphate | 203 | $127K |
| Semaglutide | 112 | $123K |
| Rivaroxaban | 157 | $98K |
| Insulin Degludec | 57 | $49K |
| Dextromethorphan Hbr/Quinidine | 63 | $48K |
| Insulin Lispro | 50 | $44K |
| Empagliflozin | 41 | $37K |
| Insulin Detemir | 48 | $32K |
| Fluticasone/Umeclidin/Vilanter | 46 | $32K |
| Sacubitril/Valsartan | 27 | $30K |
| Semaglutide | 19 | $27K |
| Insulin Glargine,hum.Rec.Anlog | 45 | $24K |
Prescribing Profile
Patient Profile
73
Avg Age
59%
Female
1.37
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About